We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+22.34%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$307M
AUM Growth
-$14.5M
Cap. Flow
-$55.8M
Cap. Flow %
-18.15%
Top 10 Hldgs %
77.46%
Holding
48
New
4
Increased
17
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
OMER icon
Omeros
OMER
+$18.4M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$5.17M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.68M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.58M
5
KITE
Kite Pharma, Inc.
KITE
+$3.06M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$33.5M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$15.3M
3
ARWR icon
Arrowhead Research
ARWR
+$12.1M
4
BLUE
bluebird bio
BLUE
+$11.3M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$5.46M

Sector Composition

Rank Sector Weight
1 Healthcare 79.43%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMBR
26
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$563K 0.18%
25
– –
GHDX
27
DELISTED
Genomic Health, Inc.
GHDX
$528K 0.17%
15,000
– –
NTRA icon
28
Natera
NTRA
$38.7B
$342K 0.11%
31,693
– –
BLUE
29
DELISTED
bluebird bio
BLUE
$340K 0.11%
409
-11,294
-97% -$11.3M
ALPN
30
DELISTED
Alpine Immune Sciences Inc
ALPN
$232K 0.08%
7,500
– –
TTOO
31
DELISTED
T2 Biosystems, Inc
TTOO
$229K 0.07%
+4
New +$216K
VCYT icon
32
Veracyte
VCYT
$3.61B
$180K 0.06%
25,000
– –
ELGX
33
DELISTED
Endologix Inc
ELGX
$149K 0.05%
1,500
– –
VIVO
34
CALL
DELISTED
Meridian Bioscience Inc
VIVO
$110K 0.04%
1,252
– –
ADAP
35
DELISTED
Adaptimmune Therapeutics
ADAP
$85K 0.03%
7,055
+27
+0.4% +$264
NVRO
36
PUT
DELISTED
NEVRO CORP.
NVRO
$37K 0.01%
+142
New +$7.6K
BRK.B icon
37
Berkshire Hathaway Class B
BRK.B
$1.11T
$7K ﹤0.01%
50
– –
USO icon
38
CALL
United States Oil Fund
USO
$1.91B
$7K ﹤0.01%
1,731
– –
ARWR icon
39
Arrowhead Research
ARWR
$12.1B
– –
-2,097,185
Closed -$12.1M
BCRX icon
40
CALL
BioCryst Pharmaceuticals
BCRX
$2.24B
– –
-2,000
Closed -$431K
BMY icon
41
CALL
Bristol-Myers Squibb
BMY
$134B
– –
-7,500
Closed -$2.59M
GYRE icon
42
Gyre Therapeutics
GYRE
$681M
– –
-3,385
Closed -$1.77M
INCY icon
43
Incyte
INCY
$24B
– –
-303,212
Closed -$33.5M
OSUR icon
44
OraSure Technologies
OSUR
$286M
– –
-322,996
Closed -$1.43M
LUMO
45
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-3,143
Closed -$1.01M
VBIV
46
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
– –
-21,667
Closed -$1.72M
RPRX
47
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-232,830
Closed -$1.73M
LENS
48
DELISTED
Presbia PLC Ordinary Shares
LENS
– –
-350,000
Closed -$1.92M
1
2

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q4 2015 Portfolio in Review

As of Q4 2015, RTW Investments held 48 positions worth $307M, down 4.5% from $322M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

RTW Investments withdrew a net $55.8M in Q4 2015, closing 10 positions and reducing 6 holdings. Its most notable exit was Incyte, an estimated $33.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 84% a quarter earlier, followed by Financials.

Against the trend, RTW Investments opened a new position in Accelerate Diagnostics worth $2.31M.

  • RTW Investments's largest Q4 2015 buy was Accelerate Diagnostics: 10,747 shares worth $2.31M.
  • RTW Investments added most to Omeros in Q4 2015, an estimated $18.4M increase.
  • RTW Investments's biggest Q4 2015 reduction was Five Prime Therapeutics, Inc., cutting an estimated $15.3M.
  • RTW Investments fully exited Incyte in Q4 2015, selling an estimated $33.5M.
  • RTW Investments's ten largest holdings make up 77% of its $307M portfolio in Q4 2015.
  • RTW Investments opened 4 new positions and closed 10 in Q4 2015.
  • RTW Investments's portfolio value fell 4.5% quarter-over-quarter to $307M.

Based on RTW Investments's 13F filing for Q4 2015, filed 16 Feb 2016.